Anixa Biosciences Inc (ANIX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Anixa Biosciences Inc stock (ANIX) is currently trading at $2.59. Anixa Biosciences Inc PS ratio (Price-to-Sales) is 377.78. Analyst consensus price target for ANIX is $10.75. WallStSmart rates ANIX as Sell.
- ANIX PE ratio analysis and historical PE chart
- ANIX PS ratio (Price-to-Sales) history and trend
- ANIX intrinsic value — DCF, Graham Number, EPV models
- ANIX stock price prediction 2025 2026 2027 2028 2029 2030
- ANIX fair value vs current price
- ANIX insider transactions and insider buying
- Is ANIX undervalued or overvalued?
- Anixa Biosciences Inc financial analysis — revenue, earnings, cash flow
- ANIX Piotroski F-Score and Altman Z-Score
- ANIX analyst price target and Smart Rating
Anixa Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Anixa Biosciences Inc (ANIX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Anixa Biosciences Inc (ANIX) Key Strengths (0)
Supporting Valuation Data
Anixa Biosciences Inc (ANIX) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 377.8x annual revenue
Very expensive at 5.9x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Anixa Biosciences Inc (ANIX) Detailed Analysis Report
Overall Assessment
This company scores 10/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (377.78), Price/Book (5.89) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -68.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -68.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ANIX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ANIX's Price-to-Sales ratio of 377.78x trades 286% above its historical average of 97.99x (90th percentile), historically expensive. The current valuation is 37% below its historical high of 600.83x set in Dec 2016, and 42830% above its historical low of 0.88x in Feb 2015. Over the past 12 months, the PS ratio has compressed from ~481.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Anixa Biosciences Inc (ANIX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Anixa Biosciences Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Anixa Biosciences Inc.
Bottom Line
Anixa Biosciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Anixa Biosciences Inc(ANIX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is headquartered in San Jose, California.